Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

PURPOSE: Prognosis for adult B-cell acute lymphoblastic leukemia (B-ALL) is poor, and there are currently no licensed CD19 chimeric antigen receptor (CAR) therapeutics. We developed a novel second-generation CD19-CAR (CAT19-41BB-Z) with a fast off rate, designed for more physiologic T-cell activatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Roddie, Claire, Dias, Juliana, O'Reilly, Maeve A., Abbasian, Mahnaz, Cadinanos-Garai, Amaia, Vispute, Ketki, Bosshard-Carter, Leticia, Mitsikakou, Marina, Mehra, Vedika, Roddy, Harriet, Hartley, John A., Spanswick, Victoria, Lowe, Helen, Popova, Bilyana, Clifton-Hadley, Laura, Wheeler, Graham, Olejnik, Joanna, Bloor, Adrian, Irvine, David, Wood, Leigh, Marzolini, Maria A. V., Domning, Sabine, Farzaneh, Farzin, Lowdell, Mark W., Linch, David C., Pule, Martin A., Peggs, Karl S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791810/
https://www.ncbi.nlm.nih.gov/pubmed/34464155
http://dx.doi.org/10.1200/JCO.21.00917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791810/
https://www.ncbi.nlm.nih.gov/pubmed/34464155
http://dx.doi.org/10.1200/JCO.21.00917

Ejemplares similares